Mark Leonard  Singleton net worth and biography

Mark Singleton Biography and Net Worth

CFO of Bioventus

Mark Singleton serves as the Company’s Senior Vice President, Chief Financial Officer and Principle Accounting Officer.

Mr. Singleton has more than two decades of experience in operational finance and mergers & acquisitions at large and multi-national organizations. Mark was also involved in initiating the Vascular Solutions acquisition which became a separate business unit at Teleflex.

Previous to this role, Mr. Singleton served as Vice President of Finance of Teleflex’s Vascular business where he had financial responsibility for the $1.7 billion Americas business. Prior to Teleflex, he spent nearly two decades at Lenovo/IBM, where he held a number of senior leadership positions, including EMEA CFO, Western Europe CFO, North America CFO, and Think Business Group CFO.

Mr. Singleton earned his Master of Business Administration from Duke University’s Fuqua School of Business and completed his Bachelor of Science in Finance from Purdue University.

What is Mark Leonard Singleton's net worth?

The estimated net worth of Mark Leonard Singleton is at least $1.08 million as of April 11th, 2025. Singleton owns 141,088 shares of Bioventus stock worth more than $1,075,091 as of December 5th. This net worth approximation does not reflect any other assets that Singleton may own. Additionally, Singleton receives an annual salary of $740,040.00 as CFO at Bioventus. Learn More about Mark Leonard Singleton's net worth.

How old is Mark Leonard Singleton?

Singleton is currently 54 years old. There are 3 older executives and no younger executives at Bioventus. Learn More on Mark Leonard Singleton's age.

What is Mark Leonard Singleton's salary?

As the CFO of Bioventus Inc., Singleton earns $740,040.00 per year. Learn More on Mark Leonard Singleton's salary.

How do I contact Mark Leonard Singleton?

The corporate mailing address for Singleton and other Bioventus executives is 4721 EMPEROR BOULEVARD SUITE 100, DURHAM NC, 27703. Bioventus can also be reached via phone at 919-474-6700 and via email at [email protected]. Learn More on Mark Leonard Singleton's contact information.

Has Mark Leonard Singleton been buying or selling shares of Bioventus?

Mark Leonard Singleton has not been actively trading shares of Bioventus during the last ninety days. Most recently, Mark Leonard Singleton sold 3,875 shares of the business's stock in a transaction on Friday, April 11th. The shares were sold at an average price of $7.57, for a transaction totalling $29,333.75. Following the completion of the sale, the chief financial officer now directly owns 141,088 shares of the company's stock, valued at $1,068,036.16. Learn More on Mark Leonard Singleton's trading history.

Who are Bioventus' active insiders?

Bioventus' insider roster includes John Bartholdson (Director), Katrina Church (SVP), Robert Claypoole (CEO), Anthony D'Adamio (SVP), P III (CEO), Kenneth Reali (CEO), Mark Singleton (Sr. VP), and Mark Singleton (CFO). Learn More on Bioventus' active insiders.

Are insiders buying or selling shares of Bioventus?

In the last twelve months, insiders at the sold shares 10 times. They sold a total of 83,963 shares worth more than $759,143.60. The most recent insider tranaction occured on November, 7th when Director Michelle Mcmurry-Heath sold 17,701 shares worth more than $131,341.42. Insiders at Bioventus own 33.0% of the company. Learn More about insider trades at Bioventus.

Information on this page was last updated on 11/7/2025.

Mark Leonard Singleton Insider Trading History at Bioventus

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/11/2025Sell3,875$7.57$29,333.75141,088View SEC Filing Icon  
3/24/2025Sell5,479$9.79$53,639.41131,963View SEC Filing Icon  
2/18/2025Sell6,498$10.19$66,214.62118,817View SEC Filing Icon  
12/23/2024Sell10,733$10.53$113,018.49105,162View SEC Filing Icon  
6/21/2024Sell9,219$5.57$51,349.8384,895View SEC Filing Icon  
6/17/2024Sell13,753$5.84$80,317.5263,114View SEC Filing Icon  
4/11/2024Sell4,000$4.75$19,000.0034,665View SEC Filing Icon  
3/22/2024Sell5,541$5.39$29,865.9925,665View SEC Filing Icon  
3/24/2023Sell6,044$1.27$7,675.8812,581View SEC Filing Icon  
See Full Table

Mark Leonard Singleton Buying and Selling Activity at Bioventus

This chart shows Mark Leonard Singleton's buying and selling at Bioventus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bioventus Company Overview

Bioventus logo
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $7.62
Low: $7.47
High: $7.64

50 Day Range

MA: $7.07
Low: $6.51
High: $7.79

2 Week Range

Now: $7.62
Low: $5.81
High: $11.89

Volume

251,591 shs

Average Volume

375,268 shs

Market Capitalization

$630.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79